Covid-19 Predictors: Safety of Gynecological Oncology Patients Undergoing Systemic Cancer Therapy (CO-SI-ONKO)
COVID-19-Prädiktoren: Klinische Studie Zur Sicherheit Von Gynäkologisch Onkologischen Patientinnen Unter Onkologischer Systemtherapie - CO-SI-ONKO-Studie
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Heike Jansen, Dr. med.
- Phone Number: +49-89-4140-2420
- Email: heike.jansen@tum.de
Study Locations
-
-
-
Munich, Germany, 81675
- Klinikum rechts der Isar, Frauenklinik, Technische Universität München
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- gynecological cancer
- indication for systemic cancer therapy
- patients who are legally competent and able to understand and follow instructions of the study staff
- present informed consent
Exclusion Criteria:
- no use if internet or applications
- persons who are in a dependency or employment relationship with the study center
- positive proof of COVID-19
- affection of the external auditory canal
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Telemedicine
Telemonitoring via PPG (photoplethysmography) and PROM (patient reported outcome monitoring) via app
|
description will follow
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compliance
Time Frame: 3 months
|
Compliance is defined as wearing time of the in-ear-sensor.
|
3 months
|
|
robustness of the ppg-signal
Time Frame: 3 months
|
number and duration of the ppg-signal transmitted
|
3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
number of correct- and false-positive alerts
Time Frame: 3 months
|
definition via comparison of alerts with clinical data
|
3 months
|
|
number of contacts and hospitalization rates
Time Frame: 3 months
|
definition via comparison of alerts and resulting contacts and hospitalization rates with clinical data
|
3 months
|
|
infections
Time Frame: 3 months
|
detection of infesctions via suspected ppg-signal transmitted or PRO-data.
This results in blood test zu verify acute infections.
|
3 months
|
|
therapy modifications
Time Frame: 3 months
|
dose-reductions (%), postponing of therapy cycles (time in days between actual and plannend date), therapy discontinuation
|
3 months
|
|
effect on quality of life
Time Frame: 3 months
|
change in minimum 9 points in the EORTC QLQ-C30-questionnaire is evaluated as significant change.
In questions 1-28: 28-112 points can be achieved: higher scores are associated with a worse outcome.
In questions 29-30:2-14 points can be achieved: higher scores are associated with a better outcome.
|
3 months
|
|
OS; PFS
Time Frame: 3 months
|
time between study inclusion and death; time between study inclusion and proven increasing tumor mass (number of days)
|
3 months
|
|
health-related costs
Time Frame: 3 months
|
cost-effectiveness analysis
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Heike Jansen, Dr. med, Technical University of Munich
- Study Director: Marion Kiechle, Prof. Dr. med., Technical University of Munich
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CO-SI-ONKO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.